Kiambu: Kiambu Director of Health Dr Hillary Kagwa has firmly refuted reports and propaganda circulating about the polio immunization programme, assuring Kenyans that the vaccines are safe and approved by the World Health Organization (WHO). During a stakeholder sensitization forum held over the weekend to discuss the rollout of the second round of the Polio Immunisation Campaign in nine counties in Kenya, Dr. Kagwa emphasized that the vaccine was considered a noble one medically, while there have been rare instances of children experiencing side effects related to their genetic makeup, these effects were generally manageable and in a majority of cases often resolved on their own.
According to Kenya News Agency, Dr. Kagwa explained that there is considerable misinformation surrounding the polio vaccine. He assured that these vaccines have been approved by the World Health Organization (WHO) and confirmed to be safe. He noted that adverse effects following immunization can occur with any vaccine or medication
, as individuals have varying genetic makeup, which can influence their responses.
He highlighted that due to the discovery of multiple polio cases in certain areas of Nairobi, an immunization campaign would be carried out across all seven sub-counties of Kiambu that surround the capital city. The goal is to vaccinate approximately 300,000 children under the age of 5. Children who received their vaccinations during the initial phase in October can participate in this second round to enhance their immunity.
Stakeholders from AMREF, who were also present at the event, underscored the significance of the vaccination initiative, urging parents and guardians to ensure their children receive the necessary immunizations. This follows the Ministry of Health’s announcement on Friday that the October 2024 vaccination campaign had led to the deaths of two children.
Director General for Health Dr Patrick Amoth announced that the Ministry had received 23 reports of post-vaccination events related to the campaign. The M
inistry consulted with the Kenya National Vaccines Safety Advisory Committee (KNVSAC), which convened on October 23 and 24 to evaluate all the reported cases.
Dr. Amoth explained that among the 23 reported and investigated cases, 16 were classified as non-serious, presenting symptoms such as generalized itchy rash, fever, conjunctivitis, body rashes, abdominal pain, and diarrhoea. In contrast, 7 cases were deemed serious, featuring symptoms such as fever, convulsions, and weakness in the lower limbs.
Additionally, an analysis of both serious and non-serious events indicated that all 16 of the non-serious cases had been resolved, while 5 of the serious cases were still in the process of recovery. Dr. Amoth noted that most cases of Adverse Events Following Immunization (AEFI) were categorized as coincidental, emphasizing the significance of thorough causality assessments to accurately differentiate between coincidental events and genuine vaccine-related reactions. He stated that the distinction is crucial for
maintaining public trust in the safety of the immunization program.
He observed that over 3.6 million healthy children received vaccinations during the campaign, indicating that the vaccines were largely safe.